ES2539790T3 - Métodos y composiciones para modular c-met hiperestabilizado - Google Patents

Métodos y composiciones para modular c-met hiperestabilizado Download PDF

Info

Publication number
ES2539790T3
ES2539790T3 ES06748671.2T ES06748671T ES2539790T3 ES 2539790 T3 ES2539790 T3 ES 2539790T3 ES 06748671 T ES06748671 T ES 06748671T ES 2539790 T3 ES2539790 T3 ES 2539790T3
Authority
ES
Spain
Prior art keywords
met
hyperstabilized
polypeptide
antagonist
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06748671.2T
Other languages
English (en)
Inventor
Dineli M. Wickramasinghe
Monica Kong-Beltran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37053941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2539790(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2539790T3 publication Critical patent/ES2539790T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un antagonista que inhibe la actividad de señalización de c-met de un polipéptido c-met hiperestabilizado humano, donde el polipéptido c-met hiperestabilizado comprende una deleción en marco del exón 14, la deleción que elimina el sitio de fosforilación de Y1003, tal que la degradación del polipéptido está disminuida en comparación con c-met de tipo silvestre, y donde el polipéptido c-met hiperestabilizado tiene actividad de señalización de c-met, para el uso en un método para tratar un tumor que comprende c-met hiperestabilizado en un sujeto, donde dicho método comprende administrar dicho antagonista a un sujeto, por lo que se trata el tumor, donde el antagonista es (i) un anticuerpo que se fija a un polipéptido c-met hiperestabilizado humano; o (ii) un ARN inhibidor o un oligonucleótido antisentido que inhiben la expresión de una molécula de ácido nucleico que codifica el polipéptido c-met hiperestabilizado humano.
ES06748671.2T 2005-03-25 2006-03-24 Métodos y composiciones para modular c-met hiperestabilizado Active ES2539790T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66548205P 2005-03-25 2005-03-25
US665482P 2005-03-25
PCT/US2006/010850 WO2006104911A2 (en) 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met

Publications (1)

Publication Number Publication Date
ES2539790T3 true ES2539790T3 (es) 2015-07-06

Family

ID=37053941

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06748671.2T Active ES2539790T3 (es) 2005-03-25 2006-03-24 Métodos y composiciones para modular c-met hiperestabilizado

Country Status (18)

Country Link
US (2) US7615529B2 (es)
EP (1) EP1868648B1 (es)
JP (2) JP2008535821A (es)
KR (1) KR20080000613A (es)
CN (1) CN101184506B (es)
AU (1) AU2006229989B2 (es)
BR (1) BRPI0611468A2 (es)
CA (1) CA2599988A1 (es)
ES (1) ES2539790T3 (es)
HK (1) HK1109075A1 (es)
IL (1) IL185708A (es)
MX (1) MX2007011652A (es)
NO (1) NO20075412L (es)
NZ (1) NZ561211A (es)
RU (1) RU2404193C2 (es)
SG (1) SG159547A1 (es)
WO (1) WO2006104911A2 (es)
ZA (1) ZA200707953B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080000613A (ko) * 2005-03-25 2008-01-02 제넨테크, 인크. 과안정화된 ｃ-ｍｅｔ의 조절을 위한 방법 및 조성물
SG188802A1 (en) * 2008-03-06 2013-04-30 Genentech Inc Combination therapy with c-met and egfr antagonists
NZ591087A (en) * 2008-10-01 2012-08-31 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2417159A1 (en) * 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-3/anti-c-met antibodies
BRPI1014449A2 (pt) * 2009-04-07 2017-06-27 Roche Glycart Ag anticorpos biespecíficos anti-erbb-2/ anti-c-met.
EA030182B1 (ru) 2009-04-20 2018-07-31 Оксфорд Байотерепьютикс Лтд. Антитела, специфические для кадгерина-17
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
ES2636971T3 (es) 2009-11-05 2017-10-10 F. Hoffmann-La Roche Ag Procedimientos y composición para la secreción de polipéptidos heterógenos
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
AU2011318574B2 (en) * 2010-10-20 2016-03-03 Oxford Biotherapeutics Ltd. Antibodies
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
CA2843771A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
WO2013049112A1 (en) * 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
RU2014124842A (ru) * 2011-11-21 2015-12-27 Дженентек, Инк. Очистка анти-с-мет антител
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
LT2839860T (lt) 2012-10-12 2019-07-10 Medimmune Limited Pirolobenzodiazepinai ir jų konjugatai
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
SG11201506451UA (en) 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
CN106103730B (zh) 2014-03-14 2021-06-08 豪夫迈·罗氏有限公司 用于分泌异源多肽的方法和组合物
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
US10450376B2 (en) 2014-09-16 2019-10-22 Symphogen A/S Anti-MET antibodies and compositions
GB201419108D0 (en) * 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
CN107613974B (zh) 2015-03-16 2021-01-15 塞尔德克斯医疗公司 抗-met抗体及其使用方法
CA3035932A1 (en) 2016-09-14 2018-03-22 Abbvie Biotherapeutics Inc. Anti-pd-1 antibodies and their uses
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2019224275A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
SG11202100315TA (en) 2018-07-15 2021-02-25 Enochian Biopharma Inc Methods and compositions using recombinant dendritic cells for cancer therapy
CA3131654A1 (en) 2019-02-26 2020-09-03 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
CA3146933A1 (en) 2019-09-16 2021-03-25 Marcus KELLY Radiolabeled met binding proteins for immuno-pet imaging
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN114478788A (zh) 2020-11-11 2022-05-13 高新 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
ATE423852T1 (de) 1996-04-05 2009-03-15 Antonio Giordano Methoden zur diagnose und prognose von krebs
JP2000515735A (ja) 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
EP1636593B9 (en) * 2003-06-06 2009-12-16 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
JP2008507252A (ja) * 2003-12-11 2008-03-13 ジェネンテック・インコーポレーテッド Ｃ−ｍｅｔ二量体化及び活性化を阻害するための方法と組成物
PT1718677E (pt) * 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
BRPI0612169A2 (pt) 2005-03-25 2010-10-19 Genentech Inc métodos prognósticos, métodos de detecção, de distinção, de identificação, de determinação e de monitoramento relacionados com cáncer de pulmão, métodos para amplificação de um ácido nucléico que codifica c-met humano , biomarcadores de cáncer de pulmão, agentes de imagem de cáncer de pulmão, polinucleotìdeos, agente s de ligação de antìgeno, conjuntos, meios legìveis em computador e kits e/ou artigos de fabricação
KR20080000613A (ko) 2005-03-25 2008-01-02 제넨테크, 인크. 과안정화된 ｃ-ｍｅｔ의 조절을 위한 방법 및 조성물

Also Published As

Publication number Publication date
AU2006229989A1 (en) 2006-10-05
US7615529B2 (en) 2009-11-10
CA2599988A1 (en) 2006-10-05
JP2012232979A (ja) 2012-11-29
WO2006104911A2 (en) 2006-10-05
IL185708A0 (en) 2008-01-06
EP1868648B1 (en) 2015-04-15
EP1868648A2 (en) 2007-12-26
CN101184506B (zh) 2013-07-17
RU2404193C2 (ru) 2010-11-20
RU2007139452A (ru) 2009-04-27
BRPI0611468A2 (pt) 2010-09-08
ZA200707953B (en) 2009-06-24
HK1109075A1 (en) 2008-05-30
NO20075412L (no) 2007-12-21
IL185708A (en) 2014-11-30
KR20080000613A (ko) 2008-01-02
CN101184506A (zh) 2008-05-21
US8536118B2 (en) 2013-09-17
US20100028337A1 (en) 2010-02-04
NZ561211A (en) 2011-03-31
MX2007011652A (es) 2007-11-14
AU2006229989B2 (en) 2012-02-02
US20060270594A1 (en) 2006-11-30
WO2006104911A3 (en) 2007-02-22
SG159547A1 (en) 2010-03-30
JP2008535821A (ja) 2008-09-04

Similar Documents

Publication Publication Date Title
ES2539790T3 (es) Métodos y composiciones para modular c-met hiperestabilizado
ES2542853T3 (es) Método para tratar miastenia grave
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
CL2004000720A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLIDINA-1,2-DICARBOXILDIFENILAMIDA, INHIBIDORES DE LOS FACTORES DE COAGULACION Xa, VIIa; PROCESO DE PREPARACION; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; KIT FARMACEUTICO; Y SU USO PARA TRATAR TROMBOSIS, INFAR
BRPI0412909A (pt) uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
AR058359A1 (es) Combinaciones
ECSP066421A (es) MODULACION DE LA EXPRESION DE eIF4E
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
BRPI0409128A (pt) uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
AR086510A2 (es) Agentes de union especifica al factor de crecimiento de hepatocitos
DE60329990D1 (de) Mitotische kinesin-hemmer
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
BRPI0608109A2 (pt) tratamento de distúrbios ósseos
EA200602100A1 (ru) Соединения и способы для ингибирования митотической прогрессии
YU64701A (sh) Jedinjenja upotrebljiva kao anti-inflamatorna sredstva
UY28442A1 (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y métodos para intervenir en o inhibir la proliferacion celular
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
BRPI0416981A (pt) compostos para tratamento de doenças proliferativas de célula
GT200400136A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibirlaproliferacion celular.
BRPI0518228B8 (pt) inibidores de cinesina mitótica e uso dos mesmos